by Fintan Dunne, Editor,
AidsPanelReport.com +353-87-948-9817
click
links for more
Drug corporate GlaxoSmithKline
has requested an extension of time until 31st July, 2001 to file their
defence to a 1.4 million rand damages claim on behalf of the widow of
the late James Hayman, a South African solicitor. The summons filed
4th June, 2001 by a legal team which includes barrister Anthony
Brink, attributes Hayman's death to his treatment with Glaxo's AIDS
drug AZT.
Brink's book Debating
AZT alerted President Mbeki to the dangerous toxicity of
AZT in late 1999. In October 1999 Mbeki indicted the drug's toxicity
in a statement to parliament and launched an
inquiry into it's safety.
The forthcoming action in the
South African High Court alleges for the first time that AZT is
medically ineffective
and is toxic enough of itself
to cause death. Hayman was asymptomatic
when medicated with AZT following a HIV-positive diagnosis in July 1997.
He died in June 1998 - his weight having plummeted from 68kg to 42kg
- without having contracted an AIDS-defining illness.
Should the Hayman claim succeed,
it would establish that the drug had no redeeming benefit to offset
its potentially fatal toxicity. As most AIDS patients have been medicated
with AZT, that could initiate a flood of
devastating legal actions. Glaxo had sales of almost $1 billion of AZT
last year.
The particulars of claim
in Hayman v GlaxoSmithKline allege that:
"Towards the end of July 1997 and
in Ladysmith, KwaZulu-Natal, the deceased commenced a month's course
of AZT, together with a related drug, 3TC, at daily oral doses of 600mg
and 300mg respectively,..."
"The AZT treatment immediately made
the deceased very ill, causing intractable diarrhoea and vomiting, intense
headache, profound lassitude, anaemia, muscle weakness with cramps and
pain, and progressive weight loss.
"The deceased was subsequently hospitalised
on three occasions for uncontrollable diarrhoea and vomiting without
any specific infectious aetiological agent being detected on pathological
investigation, continued to suffer profound fatigue, continued to suffer
muscular weakness and deterioration, and lose muscle mass and body weight,
and finally died on 8 June 1998 weighing 42kg.
"The deceased died as a direct result
of the cellular toxicity of AZT."
In a March 2001 open
letter to John Kearney, CEO of GlaxoSmithKline S.A, Brink asserted
that many clinical studies of the drug's effectivness "flatly refuted"
the company's claims that AZT prevents HIV replication. He also pointed
out that thirteen studies showed that human cells cannot metabolise
AZT to "anything like [the] level" required for pharmacological
effectiveness.
In an answer by Glaxo's Medical
and Corporate Affairs Director, Dr. Peter J. Moore, the company claimed
that reviews of AZT indicated it was "an effective component of
triple combination therapy".
But in reply, Brink summed up
the thrust of his forthcoming legal case: "Knowing
that AZT was synthesized in 1961 as a cell poison, why did you commence
marketing it as an antiretroviral drug in 1987 before proving
that it has this latter activity in vivo? And why have you disregarded
all studies published since, indicating that it doesnt. Especially
knowing how harmful it is."
IRISH HAEMOPHILIACS AND AZT
Brink is currently visiting Ireland to confer with a scientific group
that has filed a submission with the Lindsay Tribunal which is inquiring
into the deaths of Irish hemophiliacs. The significance of the Hayman
court action for the Lindsay Tribunal, is that HIV-positive Irish haemophiliacs
who died were treated with AZT-based drug cocktails.
The
group backing the latest Lindsay Tribunal submission includes
five eminent scientists appointed to Mbeki's Presidential AIDS Advisory
Panel and the Irish webmasters of AidsMyth.com,
Fintan Dunne and Kathy McMahon. On 21st June 2001, the group filed a
submission with the Tribunal contending that HIV-positive Irish haemophiliacs
died as a result of the side-effects of their drug treatments.
Their tribunal submission
says that clotting agent itself causes immune-suppression. They also
maintain that side-effects arising from prolonged use of corticosteroid
drugs prescribed to haemophiliacs, are indistinguishable from medical
conditions arising from HIV infection. Similarly, they contend that
side-effects of anti-HIV drugs prescribed to haemophiliacs can cause
AIDS-defining illnesses.
According to scientists in the group, haemophiliacs are particularly
prone to false-positive results from HIV-antibody tests, and furthermore
could not have become HIV infected from dried clotting agent - a view
supported by statements issued by the US Centres for Disease Control.
MORE ON LINDSAY SUBMISSION: FULL
PRESS RELEASE
Fintan Dunne, TEL: +353-87-948-9817
SEE
ALSO:
Website:
http://www.aidsmyth.com
Click for London Times story
Widow quotes Mbeki line in Aids drug suit
South African Media reports of AZT suit
http://www.suntimes.co.za/2001/07/01/politics/pol02.htm
http://www.suntimes.co.za/business/legal/2001/07/08/carmel02.asp
http://news.24.com/contentDisplay/level4Article/0,1113,2-14_1046209,00.html
http://www.bday.co.za/bday/content/direct/1,3523,879498-6078-0,00.html
Nightmare on AZT Street
http://www.chronicillnet.org/online/AZT.html
Glaxo's sham informed consent on AZT
http://www.aidsmyth.addr.com/azt.htm
Articles Questioning AZT
from Virusmyth.com
http://www.virusmyth.net/aids/index/azt.htm
AIDS Research Alliance website
http://www.aidsresearch.org/
Zidovudine (AZT, Retrovir)
http://www.natip.org/zidovudine.html